Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Stemedica Cell Technologies, Inc logo — Developing Breakthrough Progenitor Cell and Protein Therapeu...

Stemedica Cell Technologies, Inc

Developing Breakthrough Progenitor Cell and Protein Therapeutics

Founded 2005 United States San Diego, United States 16 employees Series B Total: $67.00M Biotechnology, Health Care

General Information

Company Name Stemedica Cell Technologies, Inc
Founded Year 2005
Location United States San Diego, United States
Employees 16
Industries Biotechnology, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Stemedica Cell Technologies, Inc. To contact Stemedica Cell Technologies, Inc, visit stemedica.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Stemedica Cell Technologies, Inc compare?

A PDF of Stemedica Cell Technologies, Inc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Stemedica Cell Technologies, Inc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Stemedica Cell Technologies, Inc

Stemedica Cell Technologies, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. The company has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. Additionally, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. The company's last investment was a $22.00M Series B investment at 31 December 2009. Stemedica's innovative approach and promising drug candidates demonstrate potential for addressing significant unmet medical needs in the biotechnology and healthcare industries. For more information, visit www.stemedica.com

Business keywords: biopharmaceutical, progenitor cell therapy, clinical-stage, stem cell technology, Alzheimer's disease treatment, ischemic stroke treatment, neural progenitor cells, cell therapy manufacturing, cGMP-compliant facility, clinical trials, regulatory compliance, proprietary manufacturing technology, government-licensed manufacturer, clinical-grade stem cells, medical indications

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $22.00M -
31 Dec 2009
Series A $45.00M -
20 May 2008

Stemedica Cell Technologies, Inc Alternatives & Competitors

View All Alternatives
Stemedica Cell Technologies, Inc vs
Neuralstem, Inc.
Neuralstem, Inc.

Advancing stem cell technology to treat central nervous system diseases and deliver hope for incurab...

Post-IPO Equity
3 employees
Biotechnology, Health Care
Stemedica Cell Technologies, Inc vs
Histocell. Regenerative Medicine
Histocell. Regenerative Medicine Spain

Advanced therapy medicinal products, medical devices and dermocosmetics for regenerative medicine.

Grant
41 employees
Biotechnology, Health Care
Stemedica Cell Technologies, Inc vs
Athersys
Athersys United States

Committed to developing therapies to extend and enhance the quality of life.

Post-IPO Equity
37 employees
Biopharma, Biotechnology
Compare Stemedica Cell Technologies, Inc vs Athersys
Also compare with: Stemedica Cell Technologies, Inc vs Lineage Cell Therapeutics Lineage Cell Therapeutics View all alternatives

FAQ About Stemedica Cell Technologies, Inc

Developing Breakthrough Progenitor Cell and Protein Therapeutics
Stemedica Cell Technologies, Inc was founded in 2005.
Stemedica Cell Technologies, Inc is headquartered in San Diego, United States.
Stemedica Cell Technologies, Inc operates in Biotechnology and Health Care. Its work centres on biopharmaceutical, progenitor cell therapy, clinical-stage and stem cell technology.
Stemedica Cell Technologies, Inc has approximately 16 employees.
Stemedica Cell Technologies, Inc has completed 2 funding rounds, raising a total of $67.00M. The latest funding stage is Series B.
Top alternatives and competitors to Stemedica Cell Technologies, Inc include Neuralstem, Inc., Histocell. Regenerative Medicine, Athersys, Aldagen, Inc, AZTherapies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Stemedica Cell Technologies, Inc and Neuralstem, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Stemedica Cell Technologies, Inc, https://bouncewatch.com/company/stemedica-cell-technologies-inc, updated 5 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout